IECM
VIVO

Intrinsic Edge Capital Management’s Meridian Bioscience Inc VIVO Stock Holding History

Intrinsic Edge Capital Management’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-20,000
Closed -$286K – 172
2017
Q3 		$286K Sell
20,000
-273,222
-93% -$3.9M 0.06% 112
2017
Q2 		$4.62M Buy
+293,222
New +$4.22M 1.43% 18

Other funds holding VIVO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Intrinsic Edge Capital Management's VIVO Position: Q4 2017 in Review

Intrinsic Edge Capital Management sold out of Meridian Bioscience Inc (VIVO) in Q4 2017, closing a stake of 20,000 shares — an estimated $286K sold.

Intrinsic Edge Capital Management first reported a position in VIVO in Q2 2017 and held it in 2 quarters. The position peaked at $4.62M in Q2 2017. 178 funds tracked by Wall St. Rank hold VIVO as of Q4 2017.

  • Intrinsic Edge Capital Management reported no remaining Meridian Bioscience Inc position as of Q4 2017 after selling out during the quarter.
  • Intrinsic Edge Capital Management sold 20,000 Meridian Bioscience Inc shares in Q4 2017, an estimated $286K.
  • Intrinsic Edge Capital Management first reported a position in Meridian Bioscience Inc in Q2 2017 and held it in 2 quarters.
  • Intrinsic Edge Capital Management's Meridian Bioscience Inc position peaked at $4.62M in Q2 2017.
  • 178 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2017.

Based on Intrinsic Edge Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.